Medline, Inc. R&D remained flat by 0.0% to $20.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.4%, from $16.75M to $20.00M. Over 2 years (FY 2023 to FY 2025), R&D shows an upward trend with a 15.5% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
High spending signals a commitment to future growth and innovation, though it reduces current period earnings.
Detailed definition
Expenses related to the development of new products, services, and technologies, as well as the improvement of existing...
Peer comparison
Tech leaders often spend a significant percentage of revenue on R&D to prevent disruption by competitors.
Metric ID:
research_and_developmentHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $60.00M | $67.00M | $80.00M |
| YoY Change | — | +11.7% | +19.4% |
Range$60.00M – $80.00M
CAGR+15.5%
Avg YoY Growth+15.5%
Median YoY Growth+15.5%
Current Streak2+ years growth
R&D at Other Companies
Frequently Asked Questions
- What is Medline, Inc. 's r&d?
- Medline, Inc. (MDLN) reported r&d of $20.00M in Q4 2025.
- How has Medline, Inc. 's r&d changed year-over-year?
- Medline, Inc. 's r&d increased by 19.4% year-over-year, from $16.75M to $20.00M.
- What is the long-term trend for Medline, Inc. 's r&d?
- Over 2 years (2023 to 2025), Medline, Inc. 's r&d has grown at a 15.5% compound annual growth rate (CAGR), from $60.00M to $80.00M.
- What does r&d mean?
- The money spent on creating new technology and improving existing products.